Skip to main content Back to Top
Advertisement

11/11/2016

Leflunomide Tablets

Reason for the Shortage

    • Apotex did not provide a reason for the shortage.
    • Heritage states the shortage is due to a delay in obtaining active ingredient.
    • Sanofi-Aventis has Arava available.
    • Winthrop has leflunomide tablets available.
    • Trigen has leflunomide tablets available.

Available Products

    • Arava tablet, Sanofi-Aventis, 10 mg, 30 count, NDC 00088-2160-30
    • Arava tablet, Sanofi-Aventis, 20 mg, 30 count, NDC 00088-2161-30
    • Leflunomide tablet, Apotex, 10 mg, 30 count, NDC 60505-2502-01
    • Leflunomide tablet, Apotex, 20 mg, 30 count, NDC 60505-2503-01
    • Leflunomide tablet, Heritage, 10 mg, 30 count, NDC 23155-0043-03
    • Leflunomide tablet, Heritage, 20 mg, 30 count, NDC 23155-0044-03
    • Leflunomide tablet, Trigen, 10 mg, 30 count, NDC 13811-0677-30
    • Leflunomide tablet, Trigen, 20 mg, 30 count, NDC 13811-0678-30
    • Leflunomide tablet, Winthrop, 10 mg, 30 count, NDC 00955-1735-30
    • Leflunomide tablet, Winthrop, 20 mg, 30 count, NDC 00955-1737-30

Estimated Resupply Dates

    • All marketed presentations are available.

Updated

Updated November 11, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. Created April 22, 2015 by Leslie Jensen, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins